| Original language | English (US) |
|---|---|
| Pages (from-to) | 276-280 |
| Number of pages | 5 |
| Journal | Journal of Managed Care and Specialty Pharmacy |
| Volume | 27 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2021 |
Bibliographical note
Funding Information:Funding for this summary was contributed by Arnold Ventures, California Health Care Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER’s annual policy summit is supported by dues from Aetna, America’s Health Insurance Plans, Anthem, Allergan, Alnylam, AstraZeneca, Biogen, Blue Shield of CA, Boehringer-Ingelheim, Cambia Health Services, CVS, Editas, Express Scripts, Genentech/ Roche, GlaxoSmithKline, Harvard Pilgrim, Health Care Service Corporation, HealthFirst, Health Partners, Johnson & Johnson (Janssen), Kaiser Permanente, LEO Pharma, Mallinckrodt, Merck, Novartis, National Pharmaceutical Council, Pfizer, Premera, Prime Therapeutics, Regeneron, Sanofi, Spark Therapeutics, and United Healthcare.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Adolescent
- Aminophenols/economics
- Aminopyridines/economics
- Benzodioxoles/economics
- Child
- Chloride Channel Agonists/economics
- Cost-Benefit Analysis
- Cystic Fibrosis/drug therapy
- Cystic Fibrosis Transmembrane Conductance Regulator/agonists
- Drug Approval/economics
- Drug Combinations
- Drug Costs
- Health Policy/economics
- Humans
- Indoles/economics
- Models, Economic
- Mutation
- Pyrazoles/economics
- Pyridines/economics
- Quinolines/economics
- Quinolones/economics
- Treatment Outcome
- United States
- United States Food and Drug Administration
PubMed: MeSH publication types
- Journal Article
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS